Detailed Narrative
Clinical Business Expansion and M&A Strategy
Strata significantly expanded its clinical services footprint in Q2 FY26, completing three bolt-on acquisitions that added over $20 million in revenue and $6.3 million in projected annualized adjusted EBITDA. These acquisitions, including Louisville Perfusion Services, Ohio Valley Perfusion Associates, and Heart and Lung Transplant National Recovery Program, strengthen the company's competitive positioning, expand its national footprint, and increase its network of experienced surgeons and perfusionists. The company is ahead of its capital deployment schedule and expects the pace of acquisitions to slow in H2 FY26.
Logistics Segment Headwinds and Mitigation
The logistics segment experienced moderated growth and a decline in gross margins in Q2 FY26, primarily due to a nonexclusive customer reducing flying, higher fuel surcharges, and unfavorable customer mix. Management anticipates a high single-digit sequential revenue decrease in Q3 FY26 for logistics but expects recovery to near Q2 levels by Q4 FY26. Initiatives are underway to structurally improve logistics gross margins back to the 20% target for FY27, including eliminating less efficient operators and optimizing supply contracts.
Integrated Service Offering and Market Position
Strata's integrated offering, combining clinical services with captive transplant logistics, is highly differentiated. The company operates a captive fleet of 35 aircraft and 55 ground vehicles, supported by a 24/7 logistics operations center. This integrated approach allows for more cost-effective and efficient service delivery, reducing customer costs and maximizing clinician productivity. The offering is also compatible with a growing list of machine perfusion devices, maintaining an equipment-agnostic strategy.
Organ Transplant Industry Trends
The industry continues to see a recovery in DCD (Donation after Circulatory Death) donors, with a low single-digit sequential increase in Q2 FY26. Heart, liver, and lung transplants are growing, largely driven by the rising penetration of Normothermic Regional Perfusion (NRP), which reached approximately 59% of DCD donors in Q2 FY26, up from 57% in Q1 FY26. NRP has been shown to result in approximately 50% more usable organs per DCD donor.
Statline Partnership for Organ Placement
Strata signed an agreement to take over Statline's transplant center organ placement customer relationships on a rolling basis over the next year. This arrangement, while not immediately material financially, provides long-term contracted attachment points with up to eight new customers, potentially leading to incremental clinical or logistics business over time⏳. The transition involves a fee per contract for customers and employees who sign on with Strata, with unit economics consistent with current business.
Financial Performance and Cash Generation
The company reported strong financial results with total revenue increasing 60.7% YoY to $72.5 million and gross profit up 68.9% YoY to $15.2 million in Q2 FY26. Adjusted EBITDA rose to $7.9 million, with a margin of 10.9%, a 140 basis point sequential increase. Strata generated $5.7 million in operating cash flow and $2.9 million in free cash flow, marking the second consecutive quarter of cash generation, with expectations for even stronger generation in the second half of the year.